Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis.

Autor: Fowlkes, J L, Serra, D M, Rosenberg, C K, Thrailkill, K M

Publikováno v: Journal of Biological Chemistry; November 1995, Vol. 270 Issue: 46 p27481-8, 8p

Dementia with Lewy bodies and Alzheimer's disease.

Autor: Rosenberg CK; Bryan Alzheimer's Disease Research Center, Department of Medicine, Division of Neurology, Box 2900, Duke University Medical Center, Durham, NC 27710, USA., Cummings TJ, Saunders AM, Widico C, McIntyre LM, Hulette CM

Publikováno v: Acta neuropathologica [Acta Neuropathol] 2001 Dec; Vol. 102 (6), pp. 621-6.

Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential genetic and phenotypic heterogeneity.

Autor: Scott WK; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Grubber JM, Conneally PM, Small GW, Hulette CM, Rosenberg CK, Saunders AM, Roses AD, Haines JL, Pericak-Vance MA

Publikováno v: American journal of human genetics [Am J Hum Genet] 2000 Mar; Vol. 66 (3), pp. 922-32.

Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation.

Autor: Fowlkes JL; Department of Pediatrics, University of Kentucky College of Medicine, Lexington 40536, USA., Thrailkill KM, George-Nascimento C, Rosenberg CK, Serra DM

Publikováno v: Endocrinology [Endocrinology] 1997 Jun; Vol. 138 (6), pp. 2280-5.

Hyperbaric oxygen accelerates the neurotoxicity of 2,5-hexanedione.

Autor: Rosenberg CK, Anthony DC, Szakál-Quin G, Genter MB, Graham DG

Publikováno v: Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 1987 Feb; Vol. 87 (2), pp. 374-9.